Bausch & Lomb Corp

Bausch + Lomb Corporation announced several changes to its Board of Directors and committee assignments. Thomas J. Appio has succeeded Brent Saunders as Chairman of the Board, with Mr. Saunders continuing as a board member. Dr. Laurence Paul was appointed Lead Independent Director. Additionally, new appointments were made to various board committees, including chairs for the Nominating and Corporate Governance, Science and Technology, and Talent and Compensation Committees.

Bausch + Lomb Corporation announced significant changes to its Board of Directors, appointing four new members, including Bausch Health CEO Thomas J. Appio, at the request of its controlling shareholder. Concurrently, four directors resigned, with their departures not attributed to any disagreements. The company also reported strong second-quarter financial results, with revenue increasing to $1.394 billion and net cash from operations significantly improving. Bausch + Lomb reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance.

Bausch + Lomb reported Q2 2026 revenues of $1.39 billion, an increase from $1.28 billion in Q2 2025. The company significantly reduced its net loss, reporting $(14) million for the quarter, compared to $(62) million in the prior year period. For the six months ended June 30, 2026, revenues reached $2.64 billion, and net cash provided by operating activities increased substantially to $185 million. The company continues to evaluate the separation from Bausch Health Companies Inc.

Bausch + Lomb Corporation announced strong second-quarter 2026 financial results, with total revenue increasing 9% to $1.394 billion. The company significantly improved its GAAP net loss to $14 million and reported Adjusted EBITDA of $241 million. Reflecting this performance, Bausch + Lomb raised its full-year 2026 revenue and Adjusted EBITDA guidance. The company also shared positive topline results from a pivotal clinical study for its enVista Beyond™ investigational IOL.

Bausch & Lomb Corp reported Q1 2026 revenues of $1.24 billion, an increase from $1.14 billion in Q1 2025. The company significantly reduced its net loss to $(70) million, or $(0.20) per share, compared to a net loss of $(211) million, or $(0.60) per share, in the prior year period. Operating income improved to $33 million from an operating loss of $(83) million year-over-year, and cash flow from operations turned positive.

Bausch + Lomb Corp. reported a significant improvement in its Q1 2026 financial performance, with total revenues increasing 9.4% to $1,244 million and net loss attributable to the company substantially reduced to $(71) million from $(212) million year-over-year. Operating income turned positive at $33 million, up from a loss of $(83) million in the prior year period. The company also noted the ongoing evaluation by Bausch Health Companies Inc. regarding the separation of Bausch + Lomb, which may include monetization, sale, or distribution of BHC's ownership interest.

Bausch & Lomb Corp reported a strong first quarter for 2026, with revenues increasing by 9.4% to $1.24 billion. The company significantly improved its operating performance, moving from an operating loss of $(83) million in Q1 2025 to an operating income of $33 million in Q1 2026. Net loss attributable to Bausch + Lomb Corporation was substantially reduced to $(71) million, a 66.5% improvement from the prior year's $(212) million loss. The company also generated $32 million in cash from operating activities, compared to using $(25) million in the same period last year, while BHC continues to evaluate the separation of Bausch + Lomb.

Bausch + Lomb Corporation announced strong first-quarter 2026 financial results, with revenue increasing 9% to $1.244 billion. The company significantly reduced its GAAP net loss to $71 million from $212 million in the prior year, driven by revenue growth and operating efficiencies. Based on this performance and a positive outlook, Bausch + Lomb raised its full-year 2026 revenue and Adjusted EBITDA guidance. Growth was notably strong in Pharmaceuticals, led by MIEBO and XIIDRA, and across its dry eye portfolio and premium intraocular lenses.